Psoriasis as a multisystem inflammatory disease

Advances in Medicine and Biology

Volumn 6, Issue , 2010, Pages 103-126

  Alexandroff, Anton B ^a   Novitskaya, Elena S ^b   Armstrong, David J ^c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b MILTON KEYNES UNIVERSITY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c ALTNAGELVIN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85017086118     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (149)

1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J.Am.Acad.Dermatol. 2009; 60: 218-24.
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
3. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 1999; 41: 401-7.
4. Griffiths CE, Christophers E, Barker JN et al. A classification of psoriasis vulgaris according to phenotype. Br. J. Dermatol. 2007; 156: 258-62.
5. Christensen TE, Callis KP, Papenfuss J et al. Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J. Invest Dermatol. 2006; 126: 2397-403.
6. Rakkhit T, Panko JM, Christensen TE et al. Plaque thickness and morphology in psoriasis vulgaris associated with therapeutic response. Br. J. Dermatol. 2009.
7. Lew W, Lee E, Krueger JG. Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br.J. Dermatol. 2004; 150: 668-76.
8. Stewart AF, Battaglini-Sabetta J, Millstone L. Hypocalcemia-induced pustular psoriasis of von Zumbusch. New experience with an old syndrome. Ann. Intern. Med. 1984; 100: 677-80.
9. Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases. Arch.Dermatol. 1991; 127: 1339-45.
10. Tobin AM, Langan SM, Collins P et al. Generalized pustular psoriasis (von Zumbusch) following the use of calcipotriol and betamethasone dipropionate ointment: a report of two cases. Clin.Exp.Dermatol. 2009; 34: 629-30.
11. Oumeish OY, Parish JL. Impetigo herpetiformis. Clin. Dermatol. 2006; 24: 101-4.
12. Guill CL, Hoang MP, Carder KR. Primary annular plaque-type psoriasis. Pediatr. Dermatol. 2005; 22: 15-8.
13. Liao PB, Rubinson R, Howard R et al. Annular pustular psoriasis--most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr. Dermatol. 2002; 19: 19-25.
14. Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int. J. Dermatol. 2008; 47: 1019-23.
15. Cassell SE, Bieber JD, Rich P et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J. Rheumatol. 2007; 34: 123-9.
16. de MR, el-Azhary R. Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis. Int. J. Dermatol. 2009; 48: 653-8.
17. Alexandroff, A. B. and Graham-Brown, R. A. C. Report from the 67th Annual Meeting of American Academy of Dermatology. Br.J. Dermatol. 2009. Ref Type: In Press
18. Kirke SM, Lowder S, Lloyd JJ et al. A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. J. Invest Dermatol. 2007; 127: 1641-6.
19. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J. Invest Dermatol. 2003; 121: 252-8.
20. Klosner G, Trautinger F, Knobler R et al. Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J. Invest Dermatol. 2001; 116: 459-62.
21. Schwarz T. 25 years of UV-induced immunosuppression mediated by T cells-from disregarded T suppressor cells to highly respected regulatory T cells. Photochem. Photobiol. 2008; 84: 10-8.
22. Enk CD, Sredni D, Blauvelt A et al. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J. Immunol. 1995; 154: 4851-6.
23. Simon JC, Cruz PD, Jr., Bergstresser PR et al. Low dose ultraviolet B-irradiated Langerhans cells preferentially activate CD4+ cells of the T helper 2 subset. J.Immunol. 1990; 145: 2087-91.
24. Kumar N, Armstrong DJ. Cardiovascular disease - the silent killer in rheumatoid arthritis. Clin. Med. 2008; 8: 384-7.
25. Hoekstra M, Haagsma CJ, Doelman CJ et al. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann. Rheum. Dis. 2005; 64: 141-3.
26. van Ede AE, Laan RF, Blom HJ et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology. (Oxford) 2002; 41: 658-65.
27. Berth-Jones J. The use of ciclosporin in psoriasis. J. Dermatolog. Treat. 2005; 16: 258-77.
28. Kanitakis J, Thivolet J. Cyclosporine. An immunosuppressant affecting epithelial cell proliferation. Arch. Dermatol. 1990; 126: 369-75.
29. Fairley JA, Fung PD, Ewing NM. Effect of ciclosporin A on epidermal keratinocytes in vitro: lack of a direct effect on calmodulin. Skin Pharmacol. 1990; 3: 149-56.
30. Chaidaroglou A, Degiannis D, Koniavitou K et al. In vitro effects of retinoids on mitogen-induced peripheral blood leucocyte responses. Arch. Dermatol. Res. 1998; 290: 205-10.
31. Dupuy P, Bagot M, Heslan M et al. Synthetic retinoids inhibit the antigen presenting properties of epidermal cells in vitro. J. Invest Dermatol. 1989; 93: 455-9.
32. Gupta AK, Goldfarb MT, Ellis CN et al. Side-effect profile of acitretin therapy in psoriasis. J. Am. Acad. Dermatol. 1989; 20: 1088-93.
33. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
34. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
35. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
36. Boehncke WH, Schon MP. Animal models of psoriasis. Clin. Dermatol. 2007; 25: 596-605.
37. Sabat R, Sterry W, Philipp S et al. Three decades of psoriasis research: where has it led us? Clin. Dermatol. 2007; 25: 504-9.
38. Sano S, Chan KS, Carbajal S et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 2005; 11: 43-9.
39. Pasparakis M, Courtois G, Hafner M et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002; 417: 861-6.
40. Zenz R, Eferl R, Kenner L et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005; 437: 369-75.
41. Albanesi C, De PO, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin. Dermatol. 2007; 25: 581-8.
42. Kocak M, Bozdogan O, Erkek E et al. Examination of Bcl-2, Bcl-X and bax protein expression in psoriasis. Int. J. Dermatol. 2003; 42: 789-93.
43. Grossman RM, Krueger J, Yourish D et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. U.S.A 1989; 86: 6367-71.
44. Sa SM, Valdez PA, Wu J et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 2007; 178: 2229-40.
45. El-Rachkidy RG, Young HS, Griffiths CE et al. Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis. J. Invest Dermatol. 2008; 128: 2219-24.
46. Boyman O, Conrad C, Dudli C et al. Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis. Br.J. Dermatol. 2005; 152: 1211-8.
47. Junghans V, Jung T, Neumann C. Human keratinocytes constitutively express IL-4 receptor molecules and respond to IL-4 with an increase in B7/BB1 expression. Exp.Dermatol. 1996; 5: 316-24.
48. Denfeld RW, Hollenbaugh D, Fehrenbach A et al. CD40 is functionally expressed on human keratinocytes. Eur. J. Immunol. 1996; 26: 2329-34.
49. Sharpe RJ, Arndt KA, Bauer SI et al. Cyclosporine inhibits basic fibroblast growth factor-driven proliferation of human endothelial cells and keratinocytes. Arch.Dermatol. 1989; 125: 1359-62.
50. Khandke L, Krane JF, Ashinoff R et al. Cyclosporine in psoriasis treatment. Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways. Arch.Dermatol. 1991; 127: 1172-9.
51. Kaplan A, Matsue H, Shibaki A et al. The effects of cyclosporin A and FK506 on proliferation and IL-8 production of cultured human keratinocytes. J. Dermatol.Sci. 1995; 10: 130-8.
52. Won YH, Sauder DN, McKenzie RC. Cyclosporin A inhibits keratinocyte cytokine gene expression. Br.J. Dermatol. 1994; 130: 312-9.
53. Morel P, Revillard JP, Nicolas JF et al. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J.Autoimmun. 1992; 5: 465-77.
54. Prinz J, Braun-Falco O, Meurer M et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991; 338: 320-1.
55. Gottlieb AB, Lebwohl M, Shirin S et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J. Am. Acad. Dermatol. 2000; 43: 595-604.
56. Weinshenker BG, Bass BH, Ebers GC et al. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J. Am. Acad. Dermatol. 1989; 20: 1132-3.
57. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am. J. Pathol. 1999; 155: 145-58.
58. Schon MP, Detmar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat.Med. 1997; 3: 183-8.
59. Davison SC, Ballsdon A, Allen MH et al. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp.Dermatol. 2001; 10: 280-5.
60. Austin LM, Ozawa M, Kikuchi T et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest Dermatol. 1999; 113: 752-9.
61. Garside P, Mowat AM. Polarization of Th-cell responses: a phylogenetic consequence of nonspecific immune defence? Immunol.Today 1995; 16: 220-3.
62. Alexandroff AB, McIntyre CA, Porter JC et al. Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer. Br. J. Cancer 1998; 77: 1806-11.
63. Onoue A, Kabashima K, Kobayashi M et al. Induction of eosinophil- and Th2-attracting epidermal chemokines and cutaneous late-phase reaction in tape-stripped skin. Exp.Dermatol. 2009.
64. Alexandroff AB, Pauriah M, Camp RD et al. More than skin deep - atherosclerosis as a systemic manifestation of psoriasis. Br.J. Dermatol. 2009; 161: 1-7.
65. Di CA, Di MP, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest Dermatol. 2009; 129: 1339-50.
66. Boniface K, Blom B, Liu YJ et al. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol.Rev. 2008; 226: 132-46.
67. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat.Immunol. 2007; 8: 950-7.
68. Ortega C, Fernandez A, Carrillo JM et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J. Leukoc. Biol. 2009; 86: 435-43.
69. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 2000; 192: 295-302.
70. Kumar V, Stellrecht K, Sercarz E. Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE). J. Exp. Med. 1996; 184: 1609-17.
71. Banham AH, Powrie FM, Suri-Payer E. FOXP3+ regulatory T cells: Current controversies and future perspectives. Eur. J. Immunol. 2006; 36: 2832-6.
72. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat.Immunol. 2008; 9: 239-44.
73. Coombes JL, Siddiqui KR, rancibia-Carcamo CV et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 2007; 204: 1757-64.
74. Wei J, Duramad O, Perng OA et al. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. U.S.A 2007; 104: 18169-74.
75. Schmidt-Weber CB, Akdis M, Akdis CA. TH17 cells in the big picture of immunology. J. Allergy Clin.Immunol. 2007; 120: 247-54.
76. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124: 823-35.
77. Baker BS, Ovigne JM, Powles AV et al. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br.J. Dermatol. 2003; 148: 670-9.
78. Alexandroff AB, Jackson AM, O’Donnell MA et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353: 1689-94.
79. Harvima IT, Nilsson G, Suttle MM et al. Is there a role for mast cells in psoriasis? Arch. Dermatol. Res. 2008; 300: 461-78.
80. Kneilling M, Rocken M. Mast cells: novel clinical perspectives from recent insights. Exp.Dermatol. 2009; 18: 488-96.
81. Alexandroff AB, Robins RA, Murray A et al. Tumour immunology: false hopes--new horizons? Immunol.Today 1998; 19: 247-50.
82. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc. Health Risk Manag. 2008; 4: 605-14.
83. Raftery G, Armstrong DJ. ‘Non solum… sed etiam’: added cardiac benefits of TNF alpha blockade in rheumatoid arthritis. J.R. Coll. Physicians Edin. 2008; 38: 108-11.
84. Urowitz MB, Bookman AA, Koehler BE et al. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 1976; 60: 221-5.
85. Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 2000; 26: 257-78.
86. Yoshizumi M, Perrella MA, Burnett JC, Jr. et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ.Res. 1993; 73: 205-9.
87. Popa C, Netea MG, van Riel PL et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res. 2007; 48: 751-62.
88. Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
89. Komai N, Morita Y, Sakuta T et al. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod.Rheumatol. 2007; 17: 385-90.
90. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007; 56: 2905-12.
91. McDonald CJ, Calabresi P. Complication of psoriasis. JAMA 1973; 224: 629.
92. McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N. Engl. J. Med. 1973; 288: 912.
93. McDonald CJ, Calabresi P. Thromboembolic disorders associated with psoriasis. Arch.Dermatol. 1973; 107: 918.
94. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
95. Prodanovich S, Kirsner RS, Kravetz JD et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch.Dermatol. 2009; 145: 700-3.
96. Gelfand JM, Dommasch ED, Shin DB et al. The risk of stroke in patients with psoriasis. J. Invest Dermatol. 2009; 129: 2411-8.
97. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br.J. Dermatol. 2008; 159: 895-902.
98. Ena P, Madeddu P, Glorioso N et al. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985; 40: 199-205.
99. Henseler T, Christophers E. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 1995; 32: 982-6.
100. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298-304.
101. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur. J. Epidemiol. 2004; 19: 225-30.
102. Shapiro J, Cohen AD, David M et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J. Am. Acad. Dermatol. 2007; 56: 629-34.
103. Cohen AD, Sherf M, Vidavsky L et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-5.
104. Brauchli YB, Jick SS, Miret M et al. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br.J. Dermatol. 2009; 160: 1048-56.
105. Jick SS, Kaye JA, Vasilakis-Scaramozza C et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9.
106. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J. Invest Dermatol. 1988; 91: 197-201.
107. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch.Dermatol. 2007; 143: 1493-9.
108. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br.J. Dermatol. 2008; 159: 1331-7.
109. Cohen AD, Dreiher J, Shapiro Y et al. Psoriasis and diabetes: a population-based cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 2008; 22: 585-9.
110. Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 2006; 55: 829-35.
111. Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006; 298: 321-8.
112. Woods KL, Samanta A, Burden AC. Diabetes mellitus as a risk factor for acute myocardial infarction in Asians and Europeans. Br. Heart J. 1989; 62: 118-22.
113. Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
114. Friedlaender M. Ocular findings. In: Psoriasis (Roenigk HH, Maibach HI, eds), 2nd edn. New York: Dekker, 1991: 83-6.
115. Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann. Rheum. Dis. 1976; 35: 354-6.
116. Paiva ES, Macaluso DC, Edwards A et al. Characterisation of uveitis in patients with psoriatic arthritis. Ann. Rheum. Dis. 2000; 59: 67-70.
117. Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity? Am. J. Ophthalmol. 2005; 139: 106-11.
118. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007; 27: 399-413.
119. Jiao Y, Xu H, Li H et al. Mesangial proliferative glomerulonephritis with or without IgA deposits: the morphological characters in psoriasis vulgaris. Nephron Clin.Pract. 2008; 108: c221-c225.
120. Zadrazil J, Tichy T, Horak P et al. IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of ‘psoriatic nephropathy’. J.Nephrol. 2006; 19: 382-6.
121. Ahuja TS, Funtanilla M, de Groot JJ et al. IgA nephropathy in psoriasis. Am. J. Nephrol. 1998; 18: 425-9.
122. Madeddu P, Ena P, Glorioso N et al. High prevalence of microproteinuria, an early index of renal impairment, in patients with diffuse psoriasis. Nephron 1988; 48: 222-5.
123. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest Dermatol. 2008; 128: 1207-11.
124. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron. Artery Dis. 2006; 17: 699-706.
125. Cheng X, Yu X, Ding YJ et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin.Immunol. 2008; 127: 89-97.
126. de Boer OJ, van der Meer JJ, Teeling P et al. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS.ONE. 2007; 2: e779.
127. Ross R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-26.
128. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
129. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005; 352: 1685-95.
130. Rho YH, Chung CP, Oeser A et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J.Rheumatol. 2008; 35: 1789-94.
131. McMahon M, Hahn BH. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr. Opin. Immunol. 2007; 19: 633-9.
132. Bruce IN. ‘Not only… but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology. (Oxford) 2005; 44: 1492-502.
133. van den Borne BE, Landewe RB, Houkes I et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum. 1998; 41: 1930-7.
134. Stern RS, Fitzgerald E, Ellis CN et al. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J. Am. Acad. Dermatol. 1995; 33: 44-52.
135. Lee E, Koo J. Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis. J. Dermatolog.Treat. 2004; 15: 8-13.
136. Prodanovich S, Ma F, Taylor JR et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J. Am. Acad. Dermatol. 2005; 52: 262-7.
137. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
138. Alexandroff AB, Gibbs S. Skin deep: report from the annual meeting of the British Society for Investigative Dermatology. Exp.Oncol. 2007; 29: 162-3.
139. Ganelina IE, Kukui LM, Nikolaewa JP et al. [Therapy of severe stenocardia with ultraviolet blood irradiation (UVB) and various action mechanisms of this therapy]. Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. 1982; 109: 470-82.
140. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 2006; 6: 358-70.
141. McCarey DW, McInnes IB, Sattar N. The antiinflammatory effects of statins. N. Engl. J. Med. 2001; 345: 1209-10.
142. McCarey DW, Sattar N, McInnes IB. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res.Ther. 2005; 7: 55-61.
143. McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 2015-21.
144. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: A pilot study. J. Am. Acad. Dermatol. 2007; 57: 529-31.
145. Cohen AD, Bonneh DY, Reuveni H et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm.Venereol. 2005; 85: 299-303.
146. Brauchli YB, Jick SS, Curtin F et al. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br.J. Dermatol. 2008; 158: 1299-307.
147. Friedewald VE, Cather JC, Gelfand JM et al. AJC editor’s consensus: psoriasis and coronary artery disease. Am. J. Cardiol. 2008; 102: 1631-43.
148. George J, Afek A, Gilburd B et al. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J. Am. Coll. Cardiol. 2001; 38: 900-5.
149. George J, Shoenfeld Y, Gilburd B et al. Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis. Circ.Res. 2000; 86: 1203-10.